Loading clinical trials...
Loading clinical trials...
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Children 5 Years of Age and Older With MPS II (Hunter Syndrome)
Conditions
Interventions
RGX-121
Locations
2
United States
University of California San Francisco, Benioff Children's Hospital
Oakland, California, United States
McGill University Heath Center
Montreal, Quebec, Canada
Start Date
March 11, 2021
Primary Completion Date
May 9, 2023
Completion Date
May 23, 2024
Last Updated
January 28, 2025
Lead Sponsor
REGENXBIO Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions